Eczema Vaccinatum

Protective murine and human monoclonal antibodies against eczema vaccinatum.

BACKGROUND Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum. ...

Implications for Eczema Vaccinatum Selective Killing of Vaccinia Virus by LL-37:

Vaccinia immune globulin ameliorates eczema vaccinatum in a murine model of atopic dermatitis

Supplemental Figure Legends 182 Figure S1. Experimental design of VIG treatment using a murine model of EV. Mice 183 were EC sensitized with OVA or saline for 7 weeks followed by inoculation of 10 7 plaque 184 forming units/mouse by skin scarification. Mice were sacrificed after 7 days of VV inoculation 185 and examined for clinical responses, viral load, serum levels of VV antibodies and cytok...

Development of Eczema Vaccinatum in Atopic Mouse Models and Efficacy of MVA Vaccination against Lethal Poxviral Infection

Smallpox vaccine based on live, replicating vaccinia virus (VACV) is associated with several potentially serious and deadly complications. Consequently, a new generation of vaccine based on non-replicating Modified vaccinia virus Ankara (MVA) has been under clinical development. MVA seems to induce good immune responses in blood tests, but it is impossible to test its efficacy in vivo in human....

Sycosis Vaccinatum, a Type of Vaccinia Folliculitis.

ReportofaCase |Ahealthy, immunocompetent30-year-oldman undergoingbasicmilitary trainingpresentedwith a4-dayhistory of a progressive vesiculopustular eruption of the anterior neck and chin. The patient denied symptoms of pruritus, burning, or fever at time of presentation. This patient hadnot receivedthesmallpoxvaccination,buthehadengaged insimulatedunarmedcombatwith individualswhohadrecentlybee...